The modern primary care clinic is a crowded, complicated place. A patient might come in for a diabetes check, leave with a referral for a sleep study, and be told to schedule a separate appointment for weight management. DirectCare AI, a South Florida startup founded in 2025, is betting it can close those gaps with a single, AI-supported platform. It offers direct-to-consumer virtual clinics for high-demand treatments like GLP-1 weight loss and testosterone replacement therapy (TRT), while also selling its remote patient monitoring software to traditional clinics [DirectCare AI].
The Dual-Pronged Wedge
DirectCare AI's strategy operates on two fronts. For patients, it functions as a virtual specialty clinic, offering online consultations with US-licensed physicians for GLP-1 medications, hormone replacement, hair loss, and sexual health. The company handles remote prescription and medication delivery [DirectCare AI]. For healthcare institutions, it sells an AI-enabled platform for Remote Patient Monitoring (RPM) and Chronic Care Management (CCM). This software aims to help primary care practices track patient vitals from home, flagging potential issues for earlier intervention [DirectCare AI].
| Segment | Offering | Key Differentiator |
|---|---|---|
| Direct-to-Consumer | Virtual clinics for GLP-1, TRT, HRT, hair loss, sexual health | Physician-supervised plans, AI personalization, medication delivery |
| Healthcare Institutions (B2B) | AI-powered RPM & CCM platforms | Helps clinics modernize care, close infrastructure gaps, and track chronic conditions |
Who Is Behind the Company
The company is led by solo founder Scott Hozebin. His public profile is anchored by a seat on the Forbes Technology Council [Forbes Councils, 2024]. Hozebin is also listed as a managing director at MetaEquity Partners and has held advisory roles, including at digital health company Better Health [Forbes Business Development Council, 2025]. The company has posted listings for marketing and data analyst interns, indicating a lean, foundational build-out [LinkedIn].
The Unanswered Questions of Scale
The ambition is clear, but the path to scaling a capital-intensive, compliance-heavy telehealth operation is lined with open questions. The most immediate is funding. DirectCare AI has not disclosed any institutional investment rounds, which could mean it is bootstrapped, funded quietly by angels, or still seeking its first major check.
- Regulatory navigation. While the company states it uses US-licensed physicians, the telehealth landscape for prescribing controlled substances is a patchwork of state laws.
- Clinical depth vs. convenience. The model prioritizes access and convenience. The risk is being perceived as a transactional medication provider rather than a comprehensive care partner.
- The institutional sale. Selling RPM software to clinics requires longer sales cycles, integration with electronic health records, and proving return on investment in a crowded market.
The company's rebuttal is that its AI layer is the differentiator. It's not just a telehealth front-end; it's the intelligence that manages titration, monitors side effects from connected devices, and helps clinicians prioritize outreach. Its success hinges on proving that its model is not just convenient, but clinically sound and sustainable beyond the initial prescription.